BeiGene, Ltd. (NASDAQ:BGNE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.

According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. “

Several other research firms also recently issued reports on BGNE. Robert W. Baird lifted their price target on BeiGene from $44.00 to $58.00 and gave the stock an “outperform” rating in a research note on Thursday, July 6th. Ladenburg Thalmann Financial Services initiated coverage on BeiGene in a research note on Monday. They set a “buy” rating and a $81.00 price target for the company. Maxim Group reaffirmed a “buy” rating and set a $52.00 price target on shares of BeiGene in a research note on Thursday, May 11th. William Blair reaffirmed an “outperform” rating on shares of BeiGene in a research note on Thursday, June 1st. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $83.00 price target on shares of BeiGene in a research note on Monday, July 10th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $74.80.

BeiGene (BGNE) traded down 6.03% during midday trading on Thursday, hitting $72.64. 512,417 shares of the stock were exchanged. BeiGene has a one year low of $26.43 and a one year high of $79.89. The firm has a 50-day moving average price of $65.71 and a 200-day moving average price of $45.09. The stock’s market cap is $2.89 billion.

ILLEGAL ACTIVITY WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/08/10/beigene-ltd-nasdaqbgne-downgraded-to-hold-at-zacks-investment-research.html.

In related news, Director Xiaodong Wang sold 20,000 shares of BeiGene stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $72.44, for a total transaction of $1,448,800.00. Following the completion of the sale, the director now owns 16,300 shares in the company, valued at approximately $1,180,772. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Donald W. Glazer sold 10,810 shares of BeiGene stock in a transaction dated Monday, July 10th. The stock was sold at an average price of $72.15, for a total value of $779,941.50. Following the sale, the director now owns 7,206 shares of the company’s stock, valued at approximately $519,912.90. The disclosure for this sale can be found here. Insiders have sold a total of 389,249 shares of company stock valued at $22,594,820 in the last ninety days. Corporate insiders own 24.20% of the company’s stock.

A number of hedge funds have recently bought and sold shares of BGNE. Guggenheim Capital LLC bought a new stake in BeiGene during the fourth quarter worth approximately $670,000. Norges Bank bought a new stake in BeiGene during the fourth quarter worth approximately $607,000. Candriam Luxembourg S.C.A. bought a new stake in BeiGene during the first quarter worth approximately $4,210,000. ProShare Advisors LLC boosted its stake in BeiGene by 42.0% in the first quarter. ProShare Advisors LLC now owns 9,872 shares of the company’s stock worth $361,000 after buying an additional 2,918 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D boosted its stake in BeiGene by 3.8% in the first quarter. State of New Jersey Common Pension Fund D now owns 45,987 shares of the company’s stock worth $1,684,000 after buying an additional 1,700 shares in the last quarter. Hedge funds and other institutional investors own 43.85% of the company’s stock.

About BeiGene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Get a free copy of the Zacks research report on BeiGene (BGNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.